Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 7455
Country/Region: Lesotho
Year: 2014
Main Partner: U.S. Department of Defense
Main Partner Program: NA
Organizational Type: Other USG Agency
Funding Agency: USDOD
Total Funding: $630,000 Additional Pipeline Funding: $550,000

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

The proposed support in COP14 continues the long standing partnership between the Lesotho Defense Force (LDF) and the US Department of Defense HIV/AIDS Prevention Program (DHAPP). This partnership began in 2001 and scaled up significantly after the introduction of Lesotho PEPFAR program in 2006, this work contributes to government national strategy to reduce new infections in adults and children, AIDS related deaths and TB deaths associated with HIV and AIDS, eliminate new infections in children and keep mothers alive. The size of the LDF is estimated at approximately 2,000 members, dispersed at military barracks throughout the country. Due to the nature of their work as well as mobility of the population, military service members are known to be at substancial risk for acquiring HIV infection. While DHAPP and more broadly continue to provide technical support, the activities of this program are planned, owned and implemented by LDF for its members. Most programs are done by LDF nurses whose salaries are paid by LDF. Drugs used in VMMC are paid by LDF. Should additional LDF resources and staff become available, additional activities could potentially be transitioned from this program to the LDF. The proposed activities continue to support improvement and implementation of LDF's capacity for data management, the quality of data collection, data reporting and data use for decision making.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $20,000
Care: TB/HIV (HVTB) $450,000
Laboratory Infrastructure (HLAB) $50,000
Testing: HIV Testing and Counseling (HVCT) $30,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $35,000
Treatment: Adult Treatment (HTXS) $45,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Age/sex: 15-19 Male 2015 500
CARE_CURR Age/sex: 20-24 Male 2015 500
CARE_CURR Age/sex: 25-49 Male 2015 3,000
CARE_CURR Age/sex: 50+ Male 2015 2,000
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 400
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 600
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 2,000
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 3,000
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 6,000
CARE_CURR Sum of Age/Sex disaggregates 2015 6,000
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 6,000
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 3,000
CARE_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 1
CARE_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services 2015 1
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 1
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 1
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 1
CARE_SITE_den Sum of Denominator Site Support Type disaggregates 2015 1
FN_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 1
FN_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 1
FN_SITE Number of PEPFAR-supported sites achieving 90% nutrition assessments that result in accurate categorization of malnutrition 2015 1
FN_SITE Sum of Numerator Support Type disaggregates 2015 1
FN_SITE Total number of PEPFAR-supported sites providing nutrition assessment, counseling and support (NACS) services 2015 1
FN_SITE_den Sum of Denominator Support Type disaggregates 2015 1
FN_THER Age: 15-17 2015 10
FN_THER Age: 18+ 2015 30
FN_THER Aggregated Age: <18 2015 10
FN_THER Aggregated Age: 18+ 2015 30
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2015 40
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2015 50
FN_THER Sum of Age disaggregates 2015 40
FN_THER Sum of Aggregated Age disaggregates 2015 40
HTS_TST Age/sex: 10-14 Male 2015 50
HTS_TST Age/sex: 15-19 Male 2015 50
HTS_TST Age/sex: 20-24 Male 2015 750
HTS_TST Age/sex: 25-49 Male 2015 2,500
HTS_TST Age/sex: 50+ Male 2015 650
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 500
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 500
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 1,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 1,500
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 2,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 1,500
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 3,000
HTS_TST By Test Result: Negative 2015 7,000
HTS_TST By Test Result: Negative 2015 3,000
HTS_TST By Test Result: Negative 2015 4,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 10,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 4,000
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 6,000
HTS_TST Sum of Age/Sex disaggregates 2015 4,000
HTS_TST Sum of Aggregated Age/Sex <15 2015 1,000
HTS_TST Sum of Aggregated Age/Sex <15 2015 1,000
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 3,000
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 5,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 4,000
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 6,000
HTS_TST Sum of Test Result disaggregates 2015 4,000
HTS_TST Sum of Test Result disaggregates 2015 6,000
HTS_TST Sum of Test Result disaggregates 2015 10,000
HTS_TST_POS By Test Result: Positive 2015 1,000
HTS_TST_POS By Test Result: Positive 2015 2,000
HTS_TST_POS By Test Result: Positive 2015 3,000
PMTCT_ARV Life-long ART (including Option B+) 2015 210
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 210
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 210
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 90
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 120
PMTCT_ARV Sum of New and Current disaggregates 2015 210
PMTCT_ARV Sum of Regimen Type disaggregates 2015 210
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 210
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 210
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 210
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 90
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 120
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 210
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 210
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 90
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 95
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 210
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 185
PMTCT_EID Sum of Infant Age disaggregates 2015 185
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 1
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 1
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 1
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 1
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 1
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 1
PMTCT_STAT By: Known positives at entry 2015 90
PMTCT_STAT By: Number of new positives identified 2015 120
PMTCT_STAT Number of new ANC and L&D clients 2015 350
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 350
PMTCT_STAT Sum of Positives Status disaggregates 2015 210
PMTCT_STAT_NGI By: Known positives at entry 2015 100
PMTCT_STAT_NGI By: Number of new positives identified 2015 100
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 350
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 350
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 200
SITE_SUPP By program area/support type: Care and Support Technical Assistance-only (TA) 2015 1
SITE_SUPP By program area/support type: Food and Nutrition Technical Assistance-only (TA) 2015 1
SITE_SUPP By program area/support type: HTC Technical Assistance-only (TA) 2015 1
SITE_SUPP By program area/support type: PMTCT Technical Assistance-only (TA) 2015 1
SITE_SUPP By program area/support type: TB/HIV Technical Assistance-only (TA) 2015 1
SITE_SUPP By program area/support type: Treatment Technical Assistance-only (TA) 2015 1
SITE_SUPP Number of unique sites supported by PEPFAR 2015 1
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units 2015 1
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 1
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 1
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 1
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 1
TB_ARTSITE_den Sum of Denominator Site Support Type disaggregates 2015 1
TX_CURR Aggregated Age/Sex: 15+ Female 2015 1,000
TX_CURR Aggregated Age/Sex: 15+ Male 2015 1,500
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 2,500
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 2,500
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 2,500
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 10
TX_DIST Total number of PEPFAR supported District Health Offices 2015 10
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 350
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 2,300
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 2,300
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 2,350
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 2,300
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 2,500
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,500
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,500
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,500
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 2,500
TX_SITE By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 1
TX_SITE By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites 2015 1
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 1
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 1
TX_SITE Total number of PEPFAR-supported ART sites 2015 1
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 1
VMMC_CIRC By Age: 10-14 2015 50
VMMC_CIRC By Age: 15-19 2015 250
VMMC_CIRC By Age: 20-24 2015 1,500
VMMC_CIRC By Age: 25-49 2015 6,000
VMMC_CIRC By Age: 50+ 2015 200
VMMC_CIRC By circumcision technique: Device-based VMMC 2015 5,000
VMMC_CIRC By circumcision technique: Surgical VMMC 2015 3,000
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 50
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 7,950
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 100
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 7,800
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 100
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 8,000
VMMC_CIRC Sum of age disaggregates 2015 8,000
VMMC_CIRC_NGI By Age: 10-14 2015 50
VMMC_CIRC_NGI By Age: 15-19 2015 250
VMMC_CIRC_NGI By Age: 20-24 2015 1,500
VMMC_CIRC_NGI By Age: 25-49 2015 6,000
VMMC_CIRC_NGI By Age: 50+ 2015 200
VMMC_CIRC_NGI By circumcision technique: Device-based VMMC 2015 5,000
VMMC_CIRC_NGI By circumcision technique: Surgical VMMC 2015 3,000
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2015 50
VMMC_CIRC_NGI By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2015 7,950
VMMC_CIRC_NGI By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2015 100
VMMC_CIRC_NGI By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2015 7,800
VMMC_CIRC_NGI By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2015 100
VMMC_CIRC_NGI Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2015 8,000
VMMC_CIRC_NGI Sum of Age disaggregates 2015 8,000
Cross Cutting Budget Categories and Known Amounts Total: $950,000
Food and Nutrition: Commodities $100,000
Construction $450,000
Gender: Gender Equality $200,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Implementation
Promoting gender-related policies and laws that increase legal protection
Collection and Use of Gender-related Strategic Information
Increase gender-equitable access to income and productive resources, including education
Equity in HIV prevention, care, treatment and support
Human Resources for Health $200,000
Key Issues Identified in Mechanism
Child Survival Activities
Military Populations
Mobile Populations
Safe Motherhood
Tuberculosis
Family Planning